Date: 2011-09-14
Type of information:
phase: 3
Announcement: authorization
Company: AB Science (France)
Product: masitinib
Action mechanism: tyrosine kinase inhibitor
Disease: asthma
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country: USA
Trial details: This international, multicenter, double-blind and placebo-controlled phase 3 study will compare efficacy and safety of masitinib to 6 mg / kg / day to placebo in the treatment of patients with persistent severe asthma uncontrolled by oral corticosteroids.
Latest news: AB Science has got an IND (Investigational New Drug) from the FDA to conduct a phase 3 study of masitinib in patients with severe persistent asthma. This study is already authorized in Europe and recruitment is ongoing. A total of around 300 patients will be included.
